451 related articles for article (PubMed ID: 2944917)
1. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
2. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
Young CW; Raymond V
Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
[No Abstract] [Full Text] [Related]
3. Anthracycline analogs: the past, present, and future.
Weiss RB; Sarosy G; Clagett-Carr K; Russo M; Leyland-Jones B
Cancer Chemother Pharmacol; 1986; 18(3):185-97. PubMed ID: 2948729
[No Abstract] [Full Text] [Related]
4. New anthracycline antitumor antibiotics.
Muggia FM; Green MD
Crit Rev Oncol Hematol; 1991; 11(1):43-64. PubMed ID: 1831987
[TBL] [Abstract][Full Text] [Related]
5. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Hurteloup P; Ganzina F
Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
[TBL] [Abstract][Full Text] [Related]
6. [Current status of clinical results of new antitumor drugs].
Ogawa M
Gan To Kagaku Ryoho; 1985 Feb; 12(2):179-88. PubMed ID: 3918502
[TBL] [Abstract][Full Text] [Related]
7. New anthracycline analogs in advanced breast cancer.
Bonfante V; Ferrari L; Brambilla C; Rossi A; Villani F; Crippa F; Valagussa P; Bonadonna G
Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1379-85. PubMed ID: 3470179
[TBL] [Abstract][Full Text] [Related]
8. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
[TBL] [Abstract][Full Text] [Related]
9. [Therapy of acute leukemia: contribution of the new anthracyclinic drugs].
Lambertenghi-Deliliers G; Colajori E; Annaloro C; Polli EE
Recenti Prog Med; 1985; 76(7-8):392-7. PubMed ID: 3906794
[No Abstract] [Full Text] [Related]
10. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetics of new anthracyclines].
Robert J
Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
[TBL] [Abstract][Full Text] [Related]
12. New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials.
Oki T; Takeuchi T; Oka S; Umezawa H
Recent Results Cancer Res; 1981; 76():21-40. PubMed ID: 6940212
[No Abstract] [Full Text] [Related]
13. Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture.
Arcamone F
Cancer Res; 1985 Dec; 45(12 Pt 1):5995-9. PubMed ID: 3864526
[TBL] [Abstract][Full Text] [Related]
14. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
[TBL] [Abstract][Full Text] [Related]
15. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
Feijen EAM; Leisenring WM; Stratton KL; Ness KK; van der Pal HJH; van Dalen EC; Armstrong GT; Aune GJ; Green DM; Hudson MM; Loonen J; Oeffinger KC; Robison LL; Yasui Y; Kremer LCM; Chow EJ
JAMA Oncol; 2019 Jun; 5(6):864-871. PubMed ID: 30703192
[TBL] [Abstract][Full Text] [Related]
16. The anthracyclines: will we ever find a better doxorubicin?
Weiss RB
Semin Oncol; 1992 Dec; 19(6):670-86. PubMed ID: 1462166
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
Jaenke RS; Deprez-DeCampeneere D; Trouet A
Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
[TBL] [Abstract][Full Text] [Related]
18. Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro.
Seeber S; Loth H; Crooke ST
J Cancer Res Clin Oncol; 1980; 98(2):109-18. PubMed ID: 6938517
[TBL] [Abstract][Full Text] [Related]
19. Menogaril: a new anthracycline agent entering clinical trials.
McGovren JP; Nelson KG; Lassus M; Cradock JC; Plowman J; Christopher JP
Invest New Drugs; 1984; 2(4):359-67. PubMed ID: 6239835
[TBL] [Abstract][Full Text] [Related]
20. [New anthracyclines].
Ogawa M; Ariyoshi Y
Gan To Kagaku Ryoho; 1993 Jan; 20(1):27-33. PubMed ID: 8422185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]